CTOs on the Move

Sonde Health

www.sondehealth.com

 
Sonde Health is a digital medicine company developing a voice-based technology platform with the potential to transform the way we monitor and diagnose mental and physical health.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Sonde Health raised $10M on 04/10/2019

Similar Companies

Proginitor Cell Therapy

Proginitor Cell Therapy is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medcura Incorporated

Medcura, Inc. has developed an advanced wound care platform that can be used across a broad spectrum of clinical and non-clinical settings. By making molecular modifications to natural biopolymers, Medcura`s patented approach provides rapid hemostasis in a clean, safe healing environment. The company has achieved milestones such as 3 FDA Clearances, 6 issued patents, and 7 peer-reviewed publications.

HemoShear Therapeutics

We are dedicated to discovering novel biological targets and developing drugs that profoundly improve the lives of people born with rare metabolic defects who are unable to sustain basic biochemical processes necessary for life.

Tyra Biosciences

Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. TYRA is using its proprietary SNÅP platform, which is optimized to enable rapid and precise refinement of structural design through iterative molecular SNÅPshots, in order to generate next-generation product candidates that are specifically designed to address acquired drug resistance and provide alternative treatment options. TYRA is initially focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. TYRA is advancing multiple product candidates toward the clinic including its lead product candidate TYRA-300, an FGFR3 inhibitor with an initial focus on patients with bladder cancer, and TYRA-200, an FGFR2 inhibitor with an initial focus on patients with intrahepatic cholangiocarcinoma who have developed drug resistance mutations from existing FGFR inhibitors.

Kindred Biosciences

KindredBio is focused on bringing groundbreaking products and innovative new technologies to veterinary medicine, because we believe our animal companions deserve the same kinds of safe and effective medicines that human family members enjoy.